An intergroup phase III trial of Ramucirumab plus Irinotecan in third or more line Beyond progression after Ramucirumab for Advanced Gastric cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Oct 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jan 2024 Results of subgroup analysis of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor nivolumab presented at the 2024 Gastrointestinal Cancers Symposium.
24 Oct 2023 Primary endpoint (Overall survival (OS)) has not been met, as per results presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 Results (From February 2019 to August 2022) assessing primary efficacy and safety of ramucirumab plus irinotecan with irinotecan in advanced gastric cancer patients, presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com